A Spirulina-Enhanced Diet Provides Neuroprotection in an α-Synuclein Model of Parkinson's Disease

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Pabon, Mibel M ^a   Jernberg, Jennifer N ^c   Morganti, Josh ^a   Contreras, Jessika ^a   Hudson, Charles E ^b   Klein, Ronald L ^d   Bickford, Paula C ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TULANE UNIVERSITY   (United States)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CHEMOKINE RECEPTOR CX3CR1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; INFLAMMATION; MICROGLIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; RAT; SPIRULINA; THERAPY EFFECT;

ALPHA-SYNUCLEIN; ANIMALS; DEPENDOVIRUS; DIET; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; INJECTIONS, INTRAVENTRICULAR; MALE; MICROGLIA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE, SECONDARY; RATS; RECEPTORS, CHEMOKINE; SPIRULINA; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

ADENO-ASSOCIATED VIRUS; CHLOROPHYTA; RATTUS; SPIRULINA;

EID: 84866494908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045256     Document Type: Article

References (46)

1. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, et al. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 46: 598-605.
2. Austin SA, Floden AM, Murphy EJ, Combs CK (2006) Alpha-synuclein expression modulates microglial activation phenotype. J Neurosci 26: 10558-10563. 26/41/10558 [pii];10.1523/JNEUROSCI.1799-06.2006 [doi].
3. Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A,et al. (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem 104: 1504-1525. JNC5087 [pii];10.1111/j.1471-4159.2007.05087.x [doi].
4. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ,et al. (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28: 7687-7698. 28/30/7687 [pii];10.1523/JNEUROSCI.0143-07.2008 [doi].
5. Gao HM, Hong JS, Zhang W, Liu B, (2002) Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 22: 782-790.
6. McGeer EG, McGeer PL, (1997) The role of the immune system in neurodegenerative disorders. [Review] [25 refs]. Movement Disorders 12: 855-858.
7. Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC (2011) The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation 8: 166. 1742-2094-8-166 [pii];10.1186/1742-2094-8-166 [doi].
8. Gemma C, Catlow B, Cole M, Hudson C, Samec A,et al. (2007) Early inhibition of TNFalpha increases 6-hydroxydopamine-induced striatal degeneration. Brain Res 1147: 240-247. S0006-8993(07)00305-8 [pii];10.1016/j.brainres.2007.02.003 [doi].
9. Zhang W, Wang T, Pei Z, Miller DS, Wu X,et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 19: 533-542. 19/6/533 [pii];10.1096/fj.04-2751com [doi].
10. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
11. Kruger R, Kuhn W, Leenders KL, Sprengelmeyer R, Muller T, et al. (2001) Familial parkinsonism with synuclein pathology: clinical and PET studies of A30P mutation carriers. Neurology 56: 1355-1362.
12. Klein RL, King MA, Hamby ME, Meyer EM, (2002) Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. Hum Gene Ther 13: 605-612.
13. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
14. Yamada T, Kawamata T, Walker DG, McGeer PL, (1992) Vimentin immunoreactivity in normal and pathological human brain tissue. Acta Neuropathologica 84: 157-162.
15. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69: 337-342. S0168-0102(11)00010-1 [pii];10.1016/j.neures.2010.12.020 [doi].
16. Casadesus G, Shukitt-Hale B, Joseph JA, (2002) Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging? Neurobiol Aging 23: 747-769.
17. Magrone T, Marzulli G, Jirillo E (2012) Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products. Curr Pharm Des 18: 34-42. BSP/CPD/E-Pub/000800 [pii].
18. Annapurna VV, Deosthale YG, Bamji MS, (1991) Spirulina as a source of vitamin A. Plant Foods Hum Nutr. 41: 125-134.
19. Careri M, Furlattini L, Mangia A, Musc M, Anklam E, et al. (2001) Supercritical fluid extraction for liquid chromatographic determination of carotenoids in Spirulina Pacifica algae: a chemometric approach. J Chromatogr A 912: 61-71.
20. Reddy CM, Bhat VB, Kiranmai G, Reddy MN, Reddanna P, et al. (2000) Selective inhibition of cyclooxygenase-2 by C-phycocyanin, a biliprotein from Spirulina platensis. Biochem Biophys Res Commun 277: 599-603.
21. Miranda MS, Cintra RG, Barros SB, Mancini FJ, (1998) Antioxidant activity of the microalga Spirulina maxima. Braz J Med Biol Res 31: 1075-1079.
22. Bhat VB, Madyastha KM, (2001) Scavenging of peroxynitrite by phycocyanin and phycocyanobilin from Spirulina platensis: protection against oxidative damage to DNA. Biochem Biophys Res Commun 285: 262-266.
23. Stromberg I, Gemma C, Vila J, Bickford PC, (2005) Blueberry- and spirulina-enriched diets enhance striatal dopamine recovery and induce a rapid, transient microglia activation after injury of the rat nigrostriatal dopamine system. Exp Neurol 196: 298-307.
24. Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, et al. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
25. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R,et al. (2004) Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol 78: 6381-6388. 10.1128/JVI.78.12.6381-6388.2004 [doi];78/12/6381 [pii].
26. Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13: 528-537. S1525-0016(05)01709-0 [pii];10.1016/j.ymthe.2005.11.015 [doi].
27. Klein RL, Dayton RD, Tatom JB, Henderson KM, Henning PP (2008) AAV8, 9, Rh10, Rh43 vector gene transfer in the rat brain: effects of serotype, promoter and purification method Mol Ther 16: 89-96. 6300331 [pii];10.1038/sj.mt.6300331 [doi].
28. West MJ, (2001) Design based stereological methods for estimating the total number of objects in histological material. Folia Morphol (Warsz) 60: 11-19.
29. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, et al. (2006) Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 9: 917-924.
30. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K,et al. (2008) Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 29: 1690-1701. S0197-4580(07)00167-4 [pii];10.1016/j.neurobiolaging.2007.04.006 [doi].
31. Su X, Federoff HJ, Maguire-Zeiss KA (2009) Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res 16: 238-254. 10.1007/s12640-009-9053-x [doi].
32. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V,et al. (2011) Alpha-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci 5: 80. 10.3389/fnins.2011.00080 [doi].
33. Stefanova N, Fellner L, Reindl M, Masliah E, Poewe W,et al. (2011) Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am J Pathol 179: 954-963. S0002-9440(11)00417-2 [pii];10.1016/j.ajpath.2011.04.013 [doi].
34. Rojanathammanee L, Murphy EJ, Combs CK (2011) Expression of mutant alpha-synuclein modulates microglial phenotype in vitro. J Neuroinflammation 8: 44. 1742-2094-8-44 [pii];10.1186/1742-2094-8-44 [doi].
35. Fellner L, Jellinger KA, Wenning GK, Stefanova N (2011) Glial dysfunction in the pathogenesis of alpha-synucleinopathies: emerging concepts. Acta Neuropathol 121: 675-693. 10.1007/s00401-011-0833-z [doi].
36. Wang Y, Chang CF, Chou J, Chen HL, Deng X, et al. (2005) Dietary supplementation with blueberries, spinach, or spirulina reduces ischemic brain damage. Exp Neurol 193: 75-84.
37. Shih SR, Tsai KN, Li YS, Chueh CC, Chan EC, (2003) Inhibition of enterovirus 71-induced apoptosis by allophycocyanin isolated from a blue-green alga Spirulina platensis. J Med Virol 70: 119-125.
38. Zujovic V, Benavides J, Vige X, Carter C, Taupin V (2000) AID-GLIA2>3.0.CO;2-V [pii].
39. Zujovic V, Schussler N, Jourdain D, Duverger D, Taupin V (2001) In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-ioprostane production induced by intracerebroventricular injection of LPS. J Neuroimmunol 115: 135-143. S0165572801002594 [pii].
40. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, et al. (1998) Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proceedings of the National Academy of Sciences of the United States of America 95: 10896-10901.
41. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC (2011) CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinflammation 8: 9. 1742-2094-8-9 [pii];10.1186/1742-2094-8-9 [doi].
42. Decressac M, Mattsson B, Bjorklund A (2012) Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 235: 306-315. S0014-4886(12)00071-4 [pii];10.1016/j.expneurol.2012.02.012 [doi].
43. Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M,et al. (2011) GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 134: 2302-2311. awr149 [pii];10.1093/brain/awr149 [doi].
44. Lo BC, Deglon N, Pralong W, Aebischer P (2004) Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis 17: 283-289. S0969-9961(04)00149-4 [pii];10.1016/j.nbd.2004.06.008 [doi].
45. Lo BC, Shorter J, Regulier E, Lashuel H, Iwatsubo T,et al. (2008) Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest 118: 3087-3097. 10.1172/JCI35781 [doi].
46. Yamada M, Mizuno Y, Mochizuki H (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Hum Gene Ther 16: 262-270. 10.1089/hum.2005.16.262 [doi].